CM24 combination improves clinical outcomes in advanced metastatic PDAC in phase II study interim data – The Cancer Letter
Purple Biotech Ltd. announced positive interim data from its randomized, controlled, open label, multicenter phase II study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma presented at a late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting. To access this subscriber-only content please log in or subscribe.If your institution […]
